At least 18 biotechs and pharmas are slated to report earnings this week. AstraZeneca plc (LSE:AZN; NYSE:AZN) is expected to post a 22% decline in 4Q13 EPS, while fellow big pharma Sanofi (Euronext:SAN; NYSE:SNY) is expected report EPS growth of 14%. AZ's revenues are expected to drop by 5% to $6.9 billion due to generic competition. Sanofi's top line is expected to be off by 1% to €8.4 billion ($11.6 billion), but the company reported a 2% decrease in SG&A costs for the